INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 432m ago
HOUSE PTR31m ago
SEC 13F31m ago
ROBINHOOD CHAIN31m ago
Corporate insider
SB

Sensenig Bethany

DirectorCIK 0001899935

EDGAR filingsOpen in network
Disclosed transactions10
Buys / sells0 / 2
Max Insider Score20
Connections2with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
8
SB
Sensenig BethanyDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
24.2K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    KalVista Pharmaceuticals, Inc.Director · Jun 11, 2026
  • Insider ofevidence
    SUPERNUS PHARMACEUTICALS, INC.Director · Feb 23, 2026
8
SB
Sensenig BethanyDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J
—
8,252 sh
Nov 2, 2026
Nov 4, 2026
traded Nov 2, 2026
+2d
SEC FORM 4

Evidence

8
SB
Sensenig BethanyDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
4,977 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

8
SB
Sensenig BethanyDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
2,989 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

8
SB
Sensenig BethanyDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
7,296 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

9
SB
Sensenig BethanyDirector
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D—
45.0K sh
Jun 11, 2026Jun 11, 2026
traded Jun 11, 2026
+0dSEC FORM 4

Evidence

0
SB
Sensenig BethanyDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M—
4,475 sh
Feb 19, 2026Feb 23, 2026
traded Feb 19, 2026
+4dSEC FORM 4

Evidence

16
SB
Sensenig BethanyDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$61K
1,217 sh
Feb 19, 2026Feb 23, 2026
traded Feb 19, 2026
+4dSEC FORM 4

Evidence

20
SB
Sensenig BethanyDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$167K
3,258 sh
Feb 19, 2026Feb 23, 2026
traded Feb 19, 2026
+4dSEC FORM 4

Evidence

0
SB
Sensenig BethanyDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M—
4,475 sh
Feb 19, 2026Feb 23, 2026
traded Feb 19, 2026
+4dSEC FORM 4

Evidence